Buspirone attenuates cyclophosphamide-induced renal dysfunction in association with alterations in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP signaling

Ahmed M. El-Dessouki, Amal Abdullah Alrashidi, Mohammad I. Jumaa, Hagar M. El-Sadek, Asmaa Ramadan, Shaimaa Fathy Mohamed Khalil, Sara Youssif Ibrahim, Nada A. Ashour, Samar H. Rizk, Omneya Galal, Nahed A. Raslan, Ahmed Mohamed Farghly, Amina Ibrahim Badawy, Shaza M. Elhusseiny, Farha M. Shaikh, Wael M. Elsaed, Hend A. Abdallah, Hany M. A. Sonpol, Shimaa M. Motawei, Eman Hamza

Open source

DOI: 10.3389/fphar.2026.1871321
Published: 2026-08-17
Container: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1871321,
  title = {Buspirone attenuates cyclophosphamide-induced renal dysfunction in association with alterations in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP signaling},
  author = {Ahmed M. El-Dessouki and Amal Abdullah Alrashidi and Mohammad I. Jumaa and Hagar M. El-Sadek and Asmaa Ramadan and Shaimaa Fathy Mohamed Khalil and Sara Youssif Ibrahim and Nada A. Ashour and Samar H. Rizk and Omneya Galal and Nahed A. Raslan and Ahmed Mohamed Farghly and Amina Ibrahim Badawy and Shaza M. Elhusseiny and Farha M. Shaikh and Wael M. Elsaed and Hend A. Abdallah and Hany M. A. Sonpol and Shimaa M. Motawei and Eman Hamza},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1871321},
  url = {https://doi.org/10.3389/fphar.2026.1871321}
}

RIS

TY  - JOUR
TI  - Buspirone attenuates cyclophosphamide-induced renal dysfunction in association with alterations in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP signaling
AU  - Ahmed M. El-Dessouki
AU  - Amal Abdullah Alrashidi
AU  - Mohammad I. Jumaa
AU  - Hagar M. El-Sadek
AU  - Asmaa Ramadan
AU  - Shaimaa Fathy Mohamed Khalil
AU  - Sara Youssif Ibrahim
AU  - Nada A. Ashour
AU  - Samar H. Rizk
AU  - Omneya Galal
AU  - Nahed A. Raslan
AU  - Ahmed Mohamed Farghly
AU  - Amina Ibrahim Badawy
AU  - Shaza M. Elhusseiny
AU  - Farha M. Shaikh
AU  - Wael M. Elsaed
AU  - Hend A. Abdallah
AU  - Hany M. A. Sonpol
AU  - Shimaa M. Motawei
AU  - Eman Hamza
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1871321
UR  - https://doi.org/10.3389/fphar.2026.1871321
ER  -

APA

El-Dessouki, A. M., Alrashidi, A. A., Jumaa, M. I., El-Sadek, H. M., Ramadan, A., Khalil, S. F. M., Ibrahim, S. Y., Ashour, N. A., Rizk, S. H., Galal, O., Raslan, N. A., Farghly, A. M., Badawy, A. I., Elhusseiny, S. M., Shaikh, F. M., Elsaed, W. M., Abdallah, H. A., Sonpol, H. M. A., Motawei, S. M., & Hamza, E. (2026). Buspirone attenuates cyclophosphamide-induced renal dysfunction in association with alterations in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP signaling. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1871321

Source records

crossref · retrieved 2026-09-25T10:39:33.536Z